New EU Approvals
Executive Summary
The Pink Sheet’s list of EU centralized approvals of new active substances now includes two new products, one of which is the injectable migraine prevention drug, Ajovy (fremanezumab). The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
You may also be interested in...
Pfizer’s Vizimpro On Course For India But Competitive Arena Awaits
Pfizer’s Vizimpro has been endorsed by an expert panel in India, paving the way for its potential introduction on the market, where other EGFR inhibitors including AstraZeneca’s Tagrisso have a head start.
Roche Among EU Fast-Track Hopefuls With Lymphoma Bispecific Mosunetuzumab
Two companies are set to learn whether the European Medicines Agency will agree that their planned EU marketing applications merit an accelerated assessment.
Amgen Strikes Early-Access Deal In England For Lung Cancer Drug Lumakras
Patients in England with non-small cell lung cancer will be the first In Europe to be offered Amgen’s KRAS G12C inhibitor.